Abstract
Carlo Patrono
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Atorvastatin, cardiovascular events, and disability-free survival in older adults
10.1056/nejmoa2607314
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
10.1016/s0140-6736(02)11600-x · 2002
Major outcomes in moder-ately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart at-tack trial (ALLHAT-LLT)
10.1001/jama.288.23.2998 · 2002
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the anglo-scandinavian cardiac outcomes trial–lipid lowering arm (ASCOT-LLA): a multi-centre randomised controlled trial
10.1016/s0140-6736(03)12948-0 · 2003
Rosuvastatin to prevent vascu-lar events in men and women with elevat-ed C-reactive protein
10.1056/nejmoa0807646 · 2008
Cholesterol lowering in intermediate-risk persons without cardiovascular disease
10.1056/nejmoa1600176 · 2016
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
10.1016/s0140-6736(18)31942-1 · 2019
Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial)
10.1136/bmjopen-2022-069915 · 2023
Effect of aspirin on disability-free survival in the healthy elderly
10.1056/nejmoa1800722 · 2018
Effect of aspirin on cardiovascular events and bleeding in the healthy elderly
10.1056/nejmoa1805819 · 2018
Role of aspirin in primary prevention of cardiovascular disease
10.1038/s41569-019-0225-y · 2019
Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease
10.1093/eurheartj/ehae324 · 2024
Assessment of ad-verse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials
10.1016/s0140-6736(25)01578-8 · 2026
No additional external references are available.